MicroIslet, Inc. (MIIS/MIIS.PK) Wrap Up:

MicroIslet, Inc., a biotechnology company, engages in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. Its islet transplantation technology, a patented technology licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection of islet cells. The company also focuses on developing and commercializing, MicroIslet-P, an injectable suspension of microencapsulated porcine insulin-producing, pancreatic islet cells for the treatment of insulin-dependent diabetes. MicroIslet, Inc. has collaborations with The Scripps Research Institute; and the California National Primate Research Center at the University of California in the area of islet cell transplantation therapies for the treatment of insulin-dependent diabetes. The company was founded in 1998 and is based in San Diego, California. On November 10, 2008, MicroIslet, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.